South Korea has accounted for a 3.6% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 4.8% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials in South Korea
Industry sponsored trials held an 81.7% share of all the clinical trials in South Korea in 2020, when compared with the ten-year average of 67.4%. Non-industry sponsored trials accounted for an 18.3% share in 2020 as against the average of 32.6% in the last ten years.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry sponsored clinical trials in South Korea
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOncology was the leading therapy area for industry sponsored clinical trials in South Korea in 2020 with a 39.4% share, as against a five-year average of 34.5% and a ten-year average of 30.9%.
Infectious Disease held a 9.8% share in 2020, over a five-year average of 8.2% and a ten-year average of 8.4%.
Metabolic Disorders held a 9.4% share in 2020, compared to a five-year average of 11.7% and a ten-year average of 12.1%. Cardiovascular held an 8.9% share in 2020, as against a five-year average of 10.0% and a ten-year average of 11.8%.
Gastrointestinal held an 8.2% share, over a five-year average of 8.6% and a ten-year average of 7.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for non-industry sponsored clinical trials in South Korea
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in South Korea in 2020 with a 30.4% share, as against a five-year average of 33.2% and a ten-year average of 30.1%.
Oncology held a 28.4% share in 2020, over a five-year average of 23.6% and a ten-year average of 23.4%.
Cardiovascular held a 16.9% share in 2020, compared to a five-year average of 10.4% and a ten-year average of 11.6%. Gastrointestinal held a 10.1% share in 2020, as against a five-year average of 9.5% and a ten-year average of 10.4%.
Musculoskeletal Disorders held an 8.1% share, over a five-year average of 8.3% and a ten-year average of 6.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead industry sponsored clinical trials in South Korea in 2020
Phase II trials held a 37.6% share of industry sponsored clinical trials in South Korea in 2020, over a five-year average of 31.9% and a ten-year average of 27.9%.
Phase III trials held a 31.7% share in 2020, as against a five-year average of 36.1% and a ten-year average of 37.4%. Phase I trials held a 19.7% share in 2020, compared to a five-year average of 17.9% and a ten-year average of 17.9%.
Phase IV trials held an 11.1% share in 2020, over a five-year average of 14.2% and a ten-year average of 16.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead non-industry sponsored clinical trials in South Korea in 2020
Phase II trials held a 56.8% share of non-industry sponsored clinical trials in South Korea in 2020, over a five-year average of 64.8% and a ten-year average of 60.0%.
Phase IV trials held a 27.7% share in 2020, as against a five-year average of 22.9% and a ten-year average of 24.7%. Phase III trials held an 8.8% share, compared to a five-year average of 6.6% and a ten-year average of 9.3%.
Phase I held a 6.8% share in 2020, over a five-year average of 5.7% and a ten-year average of 6.1%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
